CN101237855A - 将干扰素输送到哺乳动物的脂构建体 - Google Patents

将干扰素输送到哺乳动物的脂构建体 Download PDF

Info

Publication number
CN101237855A
CN101237855A CNA2006800268659A CN200680026865A CN101237855A CN 101237855 A CN101237855 A CN 101237855A CN A2006800268659 A CNA2006800268659 A CN A2006800268659A CN 200680026865 A CN200680026865 A CN 200680026865A CN 101237855 A CN101237855 A CN 101237855A
Authority
CN
China
Prior art keywords
interferon
biotin
construct
lipid construct
active component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800268659A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·劳
W·B·格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Inc
Original Assignee
SDG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SDG Inc filed Critical SDG Inc
Publication of CN101237855A publication Critical patent/CN101237855A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA2006800268659A 2005-05-23 2006-05-16 将干扰素输送到哺乳动物的脂构建体 Pending CN101237855A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68387805P 2005-05-23 2005-05-23
US60/683,878 2005-05-23
US11/384,575 2006-03-20

Publications (1)

Publication Number Publication Date
CN101237855A true CN101237855A (zh) 2008-08-06

Family

ID=39661981

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006800268659A Pending CN101237855A (zh) 2005-05-23 2006-05-16 将干扰素输送到哺乳动物的脂构建体
CN2006800268447A Expired - Fee Related CN101237854B (zh) 2005-05-23 2006-05-16 将胰岛素输送到哺乳动物的脂构建体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006800268447A Expired - Fee Related CN101237854B (zh) 2005-05-23 2006-05-16 将胰岛素输送到哺乳动物的脂构建体

Country Status (5)

Country Link
US (1) US20100129428A1 (enExample)
JP (1) JP5414270B2 (enExample)
KR (1) KR101389226B1 (enExample)
CN (2) CN101237855A (enExample)
ZA (2) ZA200710056B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531847A (ja) * 2013-09-30 2016-10-13 ウォックハート リミテッド 医薬組成物
CN107056802A (zh) * 2017-01-24 2017-08-18 河北百灵威超精细材料有限公司 N‑羟基硫代琥珀酰亚胺生物素酯及其衍生物的制备方法
JP7306718B2 (ja) * 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
AU2019205795A1 (en) * 2018-01-05 2020-07-09 Sdg, Inc. Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
AU2020271901A1 (en) * 2019-04-12 2021-11-04 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
KR102530032B1 (ko) 2019-09-18 2023-05-09 정원구 반려동물용 현탁액 조성물 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
EP1087753A4 (en) * 1998-05-19 2004-06-30 Sdg Inc TARGETED LIPOSOMAL DRUG ADMINISTRATION SYSTEM
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20040136955A1 (en) * 2002-09-05 2004-07-15 Barker Nicholas P Modified asialo-interferons and uses thereof
US20050026826A1 (en) 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides

Also Published As

Publication number Publication date
JP2009507761A (ja) 2009-02-26
JP5414270B2 (ja) 2014-02-12
KR101389226B1 (ko) 2014-04-25
KR20080043742A (ko) 2008-05-19
ZA200710055B (en) 2009-03-25
US20100129428A1 (en) 2010-05-27
CN101237854A (zh) 2008-08-06
ZA200710056B (en) 2009-03-25
CN101237854B (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
AU2015238887B2 (en) Orally bioavailable lipid-based constructs
Li et al. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor–beta on hepatic fibrosis in rats
AU2011230564B2 (en) Methods and compositions for weight loss
US10058622B2 (en) PH-sensitive peptides and their nanoparticles for drug delivery
US20100247625A1 (en) Orally Bioavailable Lipid-Based Constructs
JP2003501479A (ja) 薬 剤
CN101237855A (zh) 将干扰素输送到哺乳动物的脂构建体
JP5878922B2 (ja) 糖尿病血管合併症の治療
Meijer et al. Disease-induced drug targeting using novel peptide-ligand albumins
CN1997383B (zh) 含水母发光蛋白的组合物及使用它的方法
KR20080042045A (ko) 포유동물로의 인터페론 전달용 지질 구조물
KR20150054543A (ko) 간 표적화 나노입자, 이의 제조방법 및 이를 포함하는 약학적 조성물
US20070218117A1 (en) Supra molecular construct for delivery of interferon to a mammal
JP3002725B2 (ja) 線維芽細胞増殖因子関連ペプチドからなる医薬組成物
HK1259503A1 (en) Orally bioavailable lipid-based constructs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080806